SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor

• Main Authors: Tingting Ma (Author), Yanli Dong (Author), Lei Huang (Author), Yuanxun Yang (Author), Yan Geng (Author), Fei Fei (Author), Pinhao Xie (Author), Yu Zhao (Author), Hui Lin (Author), Zeyu Yang (Author), Yun Jin (Author), Xitong Ju (Author), Runbin Sun (Author), Juan Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Purpose: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR2285, the first oral coagulation factor XIa (FXIa) inhibitor developed in China in combination with aspirin, clopidogrel or ticagrelor in healthy subjects.Methods: This study was a single-center, randomized, d...